Evotec SE (EVO) Revenue & Revenue Breakdown
Evotec SE Revenue Highlights
Latest Revenue (Y)
$781.43M
Latest Revenue (Q)
$208.73M
Evotec SE Revenue by Period
Evotec SE Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $781.43M | 3.99% |
| 2022-12-31 | $751.45M | 21.59% |
| 2021-12-31 | $618.03M | 23.38% |
| 2020-12-31 | $500.92M | 12.20% |
| 2019-12-31 | $446.44M | 18.92% |
| 2018-12-31 | $375.40M | 45.71% |
| 2017-12-31 | $257.63M | 56.61% |
| 2016-12-31 | $164.51M | 28.85% |
| 2015-12-31 | $127.68M | 42.66% |
| 2014-12-31 | $89.50M | 4.14% |
| 2013-12-31 | $85.94M | -1.52% |
| 2012-12-31 | $87.27M | 8.91% |
| 2011-12-31 | $80.13M | 45.00% |
| 2010-12-31 | $55.26M | 29.47% |
| 2009-12-31 | $42.68M | 7.75% |
| 2008-12-31 | $39.61M | 20.46% |
| 2007-12-31 | $32.88M | -51.18% |
| 2006-12-31 | $67.35M | 5.05% |
| 2005-12-31 | $64.11M | 3211.02% |
| 2004-12-31 | $1.94M | -45.81% |
| 2003-12-31 | $3.57M | 100.00% |
| 2002-12-31 | - | 100.00% |
| 2001-12-31 | - | - |
Evotec SE generated $781.43M in revenue during NA 2023, up 3.99% compared to the previous quarter, and up 208.16% compared to the same period a year ago.
Evotec SE Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $208.73M | 3.68% |
| 2023-12-31 | $201.31M | 2.57% |
| 2023-09-30 | $196.28M | 15.27% |
| 2023-06-30 | $170.28M | -11.27% |
| 2023-03-31 | $191.92M | -20.26% |
| 2022-12-31 | $240.69M | 38.42% |
| 2022-09-30 | $173.88M | 0.98% |
| 2022-06-30 | $172.20M | 4.57% |
| 2022-03-31 | $164.67M | -11.97% |
| 2021-12-31 | $187.07M | 17.17% |
| 2021-09-30 | $159.66M | 15.51% |
| 2021-06-30 | $138.22M | 3.86% |
| 2021-03-31 | $133.09M | -5.28% |
| 2020-12-31 | $140.51M | 8.56% |
| 2020-09-30 | $129.43M | 15.99% |
| 2020-06-30 | $111.59M | -6.55% |
| 2020-03-31 | $119.40M | -4.54% |
| 2019-12-31 | $125.08M | 9.45% |
| 2019-09-30 | $114.27M | 10.69% |
| 2019-06-30 | $103.24M | -0.59% |
| 2019-03-31 | $103.85M | -1.46% |
| 2018-12-31 | $105.39M | 9.48% |
| 2018-09-30 | $96.26M | 1.57% |
| 2018-06-30 | $94.77M | 19.99% |
| 2018-03-31 | $78.98M | -8.98% |
| 2017-12-31 | $86.78M | 28.64% |
| 2017-09-30 | $67.46M | 26.77% |
| 2017-06-30 | $53.21M | 6.03% |
| 2017-03-31 | $50.18M | 14.37% |
| 2016-12-31 | $43.88M | -2.86% |
| 2016-09-30 | $45.17M | 18.95% |
| 2016-06-30 | $37.98M | 1.32% |
| 2016-03-31 | $37.48M | -5.07% |
| 2015-12-31 | $39.48M | 18.77% |
| 2015-09-30 | $33.24M | -0.53% |
| 2015-06-30 | $33.42M | 55.12% |
| 2015-03-31 | $21.54M | -29.52% |
| 2014-12-31 | $30.56M | 62.16% |
| 2014-09-30 | $18.85M | -16.13% |
| 2014-06-30 | $22.47M | 27.61% |
| 2014-03-31 | $17.61M | -31.26% |
| 2013-12-31 | $25.62M | 8.41% |
| 2013-09-30 | $23.63M | 20.40% |
| 2013-06-30 | $19.63M | 15.01% |
| 2013-03-31 | $17.06M | -26.01% |
| 2012-12-31 | $23.06M | 4.10% |
| 2012-09-30 | $22.16M | 1.00% |
| 2012-06-30 | $21.94M | 9.08% |
| 2012-03-31 | $20.11M | -1.50% |
| 2011-12-31 | $20.42M | -22.51% |
| 2011-09-30 | $26.35M | 44.30% |
| 2011-06-30 | $18.26M | 20.87% |
| 2011-03-31 | $15.11M | -8.01% |
| 2010-12-31 | $16.42M | 18.38% |
| 2010-09-30 | $13.87M | -8.30% |
| 2010-06-30 | $15.13M | 53.71% |
| 2010-03-31 | $9.84M | -27.36% |
| 2009-12-31 | $13.55M | 30.32% |
| 2009-09-30 | $10.40M | -1.00% |
| 2009-06-30 | $10.50M | 27.47% |
| 2009-03-31 | $8.24M | -42.95% |
| 2008-12-31 | $14.44M | 35.49% |
| 2008-09-30 | $10.66M | 47.85% |
| 2008-06-30 | $7.21M | -1.43% |
| 2008-03-31 | $7.31M | -24.85% |
| 2007-12-31 | $9.73M | - |
Evotec SE generated $208.73M in revenue during Q1 2024, up 3.68% compared to the previous quarter, and up 86.72% compared to the same period a year ago.
Evotec SE Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| EVO | Evotec SE | $781.43M | $208.73M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| SUPN | Supernus Pharmaceuticals | $607.52M | $168.32M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| SSIC | Silver Spike Investment | $11.72M | $2.76B |
| RGC | Regencell Bioscience | - | - |
EVO Revenue FAQ
What is Evotec SE’s yearly revenue?
Evotec SE's yearly revenue for 2023 was $781.43M, representing an increase of 3.99% compared to 2022. The company's yearly revenue for 2022 was $751.45M, representing an increase of 21.59% compared to 2021. EVO's yearly revenue for 2021 was $618.03M, representing an increase of 23.38% compared to 2020.
What is Evotec SE’s quarterly revenue?
Evotec SE's quarterly revenue for Q1 2024 was $208.73M, a 3.68% increase from the previous quarter (Q4 2023), and a 8.76% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $201.31M, a 2.57% increase from the previous quarter (Q3 2023), and a -16.36% decrease year-over-year (Q4 2022). EVO's quarterly revenue for Q3 2023 was $196.28M, a 15.27% increase from the previous quarter (Q2 2023), and a 12.88% increase year-over-year (Q3 2022).
What is Evotec SE’s revenue growth rate?
Evotec SE's revenue growth rate for the last 3 years (2021-2023) was 26.44%, and for the last 5 years (2019-2023) was 75.04%.